These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31583272)

  • 1. Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
    Collin LJ; Yan M; Jiang R; Ward KC; Crawford B; Torres MA; Gogineni K; Subhedar PD; Puvanesarajah S; Gaudet MM; McCullough LE
    NPJ Breast Cancer; 2019; 5():32. PubMed ID: 31583272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial Disparities in Breast Cancer Outcomes in the Metropolitan Atlanta Area: New Insights and Approaches for Health Equity.
    Collin LJ; Jiang R; Ward KC; Gogineni K; Subhedar PD; Sherman ME; Gaudet MM; Breitkopf CR; D'Angelo O; Gabram-Mendola S; Aneja R; Gaglioti AH; McCullough LE
    JNCI Cancer Spectr; 2019 Sep; 3(3):pkz053. PubMed ID: 32328557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
    Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score.
    Huang HC; Calip GS; Weiss J; Simons Y; Gadi VK; Danciu OC; Rauscher GH; Hoskins KF
    J Natl Compr Canc Netw; 2024 Jan; 22(1D):e237077. PubMed ID: 38190799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
    Collin LJ; Jones J; Nash R; Switchenko JM; Ward KC; McCullough LE
    Breast Cancer Res Treat; 2024 Jun; 205(3):609-618. PubMed ID: 38517602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
    Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
    Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
    Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receipt of Guideline-Concordant Care Does Not Explain Breast Cancer Mortality Disparities by Race in Metropolitan Atlanta.
    Collin LJ; Yan M; Jiang R; Gogineni K; Subhedar P; Ward KC; Switchenko JM; Lipscomb J; Miller-Kleinhenz J; Torres MA; Lin J; McCullough LE
    J Natl Compr Canc Netw; 2021 Aug; 19(11):1242-1251. PubMed ID: 34399407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
    Han Y; Miao ZF; Lian M; Peterson LL; Colditz GA; Liu Y
    Breast Cancer Res Treat; 2020 Dec; 184(3):915-925. PubMed ID: 32929567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
    Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
    J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
    Hoskins KF; Danciu OC; Ko NY; Calip GS
    JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A balancing act: racial disparities in cardiovascular disease mortality among women diagnosed with breast cancer.
    Collin LJ; Troeschel AN; Liu Y; Gogineni K; Borger K; Ward KC; McCullough LE
    Ann Cancer Epidemiol; 2020 Mar; 4():. PubMed ID: 32954254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.
    Iles K; Roberson ML; Spanheimer P; Gallagher K; Ollila DW; Strassle PD; Downs-Canner S
    NPJ Breast Cancer; 2022 Mar; 8(1):27. PubMed ID: 35232996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drivers of racial, regional, and socioeconomic disparities in late-stage breast cancer mortality.
    Moubadder L; Collin LJ; Nash R; Switchenko JM; Miller-Kleinhenz JM; Gogineni K; Ward KC; McCullough LE
    Cancer; 2022 Sep; 128(18):3370-3382. PubMed ID: 35867419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS).
    Casasanta N; Patel R; Raymond S; Kier MW; Blanter J; Sohval S; Hovstadius M; Wu C; Zimmerman B; Cascetta K; Bagiella E; Tiersten A
    Clin Breast Cancer; 2024 Oct; 24(7):585-596. PubMed ID: 38971641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.